A Link Between Air Pollution and Dementia Risk Is Supplied by New Data.

Published Date: 23 Apr 2023

According to the study, prolonged exposure to nitrogen dioxide, particulate matter PM2.5, and nitrogen oxide may raise the risk of dementia.

Read Full News

Latest News

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD Sara Assaf, MD

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Lungcast: Resilience and Sustainability: Preparing Healthcare for the Future with Elizabeth Cerceo, MD Albert Rizzo, MD, Elizabeth Cerceo, MD

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

Long-Term Data Support New Zopapogene Imadenovec Approval for RRP Victoria Johnson

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Nerandomilast Approval Breaks Decade-Long Dry Spell for IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

Mucoactives Found to Have Little Benefit for Bronchiectasis Victoria Johnson

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

Todays Updates

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission Marco Meglio

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

Episode 155: Understanding Variability in Infantile Spasms Care Marco Meglio, Christina Briscoe, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]

Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine Isabella Ciccone, MPH

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

NeurologyLive® Friday 5 — November 28, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

Sparsentan's Effect on Urinary Biomarkers in IgAN, With Chee Kay Cheung, MBChB, PhD Chee Kay Cheung, MBChB, PhD

Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Todays Updates

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission Marco Meglio

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

Episode 155: Understanding Variability in Infantile Spasms Care Marco Meglio, Christina Briscoe, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]

Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine Isabella Ciccone, MPH

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

NeurologyLive® Friday 5 — November 28, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

Sparsentan's Effect on Urinary Biomarkers in IgAN, With Chee Kay Cheung, MBChB, PhD Chee Kay Cheung, MBChB, PhD

Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Latest News

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

News All Time

Clinical and Patient Definitions of Acute COPD Exacerbation Recovery Differ Greatly Kevin Kunzmann

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Dupilumab Lessens COPD Exacerbation Impact, with Nicola Hanania, MD, MS Nicola Hanania, MD, MS

Hanania discusses the pooled BOREAS and NOTUS post hoc data showing dupilumab protects lung function before and after COPD exacerbations.

Extended-Release Nalbuphine Improves Patient-Reported Refractory Chronic Cough Within 1 Week Imran Satia, MD, PhD

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

Baseline Type 2 Biomarkers Can Predict Asthma Remission with Dupilumab, with Mario Castro, MD, MPH Kevin Kunzmann

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.

Dry Powder Treprostinil Tolerated Among Patients with PH-ILD, with Nicholas Kolaitis, MD Kevin Kunzmann

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Aroxybutynin and Atomoxetine (AD109) Reduces Obstructive Sleep Apnea Burden in Phase 3 SynAIRgy Kevin Kunzmann

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

From Slowing Decline to Restoring Function: Taladegib’s Promise in IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.

Dupilumab Reduces Mucus Burden in Uncontrolled Asthma, with Njira Lugogo, MD Njira Lugogo, MD

Mucus plugs are an increasingly present issue in uncontrolled asthma. Lugogo discusses promising findings from VESTIGE that addresses them.

Dupilumab Bests Omalizumab in Airway Improvement for Patients with CRSwNP and Asthma Kevin Kunzmann

Data from the phase 4 head-to-head EVEREST trial further indicates dupilumab's benefit for type 2 inflammatory airway disease.

Defining the Future of Asthma Remission, With Linda Rogers, MD

Defining the Future of Asthma Remission, With Linda Rogers, MD

The Asthma and COPD Precision Medicine Era, with Nicola A. Hanania, MD, MS

The Asthma and COPD Precision Medicine Era, with Nicola A. Hanania, MD, MS

Personalized COPD Treatment: Lessons from Biologic Trials and Clinical Practice

Personalized COPD Treatment: Lessons from Biologic Trials and Clinical Practice

Early morning practices linked to less and lower-quality sleep in college athletes

A study using more than 27,000 sleep records of collegiate athletes provides the best evidence to date that early morning team practices take a toll on healthy sleep.

Dreaming of fewer running injuries? Start with better sleep

If you are among the 620 million people who lace up their running shoes on a regular basis, chances are that you're an early riser.

Daylight robbery? How London's skyscrapers deprive marginalized people of light

When you look at the promotional materials advertising luxury high-rise developments in London, it is obvious that the fantasy of living in the sky is fused by a desire for sunlight and "unobstructed" views of the city. Phrases ...

Chronic fatigue syndrome linked to high rates of dysfunctional breathing patterns

Chronic fatigue syndrome leaves patients exhausted and struggling with brain fog—and it typically gets worse after mental or physical exercise, a phenomenon called post-exertional malaise.

Recommended News For You

In a recent study, Kencur ginger's anti-cancer properties were discovered.

Axatilimab Demonstrates Effectiveness in Refractory/Recurrent GVHD.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

Breast density changes over time are associated with an increased risk of cancer.

Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models

Applications are being accepted for TN Health's post-doctoral fellowship program in gynecologic oncology and minimal access surgery; complete details are available here.

younger kidney cancer survivors are more susceptible to heart problems.

Recommended Articles For You

Gene Signatures and Their Implications in Oncology: Decoding the Blueprint for Personalized Cancer Treatment 

Toripalimab + Nab-Paclitaxel in PD-L1+ TNBC: Phase 3 TORCHLIGHT Trial Results 

Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways 

AI and Optical Advances: Evolving Blood Cell Morphology Observation in Hematology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Distribution of fat could influence cancer risk, study suggests

2.

Study looks into cancer-related harmful communication.

3.

Q&A: When will individuals be able to receive customized cancer vaccines?

4.

Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness

5.

An Eye Surgeon's Unexpected Discovery of the "Before and After".

1.

Lymphomatoid Papulosis: What You Need to Know

2.

Understanding Hemosiderosis: Causes, Symptoms, and Treatment Options

3.

Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial

4.

Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy 

5.

Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

2.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III

3.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

4.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

5.

The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot